Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
Expert Review of Cardiovascular Therapy|July 28, 2020
Correlation between myocardial strain and adverse remodeling in a non-diabetic model of heart failure following empagliflozin therapyAlvaro Garcia-Ropero, Carlos G Santos-Gallego, Ariana P Vargas-Delgado, et al.
Cardiovascular Revascularization Medicine : Including Molecular Interventions|May 2, 2020
Clinical Prognosis Associated With the Use of Overlapping Stents With Homogenous Versus Heterogeneous Pharmacological Characteristics for the Treatment of Diffuse Coronary Artery DiseaseJosé Abellán-Huerta, Alfonso Jurado-Román, Fernando Lozano-Ruiz-Poveda, et al.
Circulation. Cardiovascular Imaging|April 12, 2023
Cardioprotective Effect of Empagliflozin and Circulating Ketone Bodies During Acute Myocardial InfarctionCarlos G Santos-Gallego, Juan Antonio Requena-Ibáñez, Belen Picatoste, et al.
European Heart Journal|February 5, 2025
Anaemia predicts iron homoeostasis dysregulation and modulates the response to empagliflozin in heart failure with reduced ejection fraction: the EMPATROPISM-FE trialChristiane E Angermann, Susanne Sehner, Louisa M S Gerhardt, et al.
Human Fertility (Cambridge, England)|April 14, 2010
Could the addition of hp-hMG and GnRH antagonists modulate the response in IVF-ICSI cycles?Antonio Requena, José L Landeras, Luis Martínez-Navarro, et al.
Human Reproduction Update|September 25, 2008
Use of letrozole in assisted reproduction: a systematic review and meta-analysisAntonio Requena, Julio Herrero, José Landeras, et al.
Cardiovascular Revascularization Medicine : Including Molecular Interventions|September 24, 2018
Comparison of Clinical Outcomes Between Very Long Stents and Overlapping Stents for the Treatment of Diffuse Coronary Disease in Real Clinical PracticeAlfonso Jurado-Román, José Abellán-Huerta, Juan Antonio Requena, et al.
Journal of the American College of Cardiology|April 20, 2019
Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial EnergeticsCarlos G Santos-Gallego, Juan Antonio Requena-Ibanez, Rodolfo San Antonio, et al.
Nature Cardiovascular Research|August 28, 2024
Empagliflozin effects on iron metabolism as a possible mechanism for improved clinical outcomes in non-diabetic patients with systolic heart failureChristiane E Angermann, Carlos G Santos-Gallego, Juan Antonio Requena-Ibanez, et al.
JACC. Heart Failure|July 30, 2021
Mechanistic Insights of Empagliflozin in Nondiabetic Patients With HFrEF: From the EMPA-TROPISM StudyJuan Antonio Requena-Ibáñez, Carlos G Santos-Gallego, Anderly Rodriguez-Cordero, et al.
Pageof 7